COGNITION THERAPEUTICS INC — Form 8-K
Filed October 22, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Cognition Therapeutics announced FDA agreement on key Phase 3 trial parameters for zervimesine (CT1812) in dementia with Lewy bodies (DLB): 100 mg once-daily oral dosing for 9 months in mild-to-moderate DLB patients, randomized to drug or placebo. Primary endpoint is neuropsychiatric inventory measuring hallucinations/delusions; secondary is ADCS-ADL functional scale. DLB has no approved treatments; ~1.4M Americans affected. Zervimesine showed disease-progression slowing in Phase 2 SHIMMER trial.
Why this rating
FDA alignment de-risks pivotal trial path for clinical-stage biotech with $18.2M market cap. Lead candidate progresses toward potential first-in-class DLB treatment; success would materially transform business trajectory and valuation.
Price action (we called it positive)
before filing · preread $0.79 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.